Oyster Point Pharma to Present at the Cowen 40th Annual Healthcare Conference
To access the live webcast of the presentation, please visit the Events & Presentations page within the Investors section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/ .
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey Nau, PhD, MMS, President and CEO, is scheduled to present at the Cowen 40th Annual Healthcare Conference on Monday, March 2, 2020 at 1:30 p.m. Eastern Time at the Boston Marriott Copley Place in Boston, MA.
To access the live webcast of the presentation, please visit the “Events & Presentations” page within the “Investors” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/. Replays of the webcast will be available on the Oyster Point Pharma website for approximately 30 days following the presentation.
About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).
Media contact:
Lisa Rivero
Syneos Health
(781) 425-4676
[email protected]
Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
[email protected]
